Undenatured virus-free biologically active protein derivatives
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
A61K-035/14
A61K-037/00
C07G-007/00
C07C-103/52
출원번호
US-0514375
(1983-07-14)
발명자
/ 주소
Neurath, Alexander R.
Horowitz, Bernard
출원인 / 주소
New York Blood Center, Inc.
대리인 / 주소
Sprung Horn Kramer & Woods
인용정보
피인용 횟수 :
109인용 특허 :
3
초록▼
A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein act
A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.
대표청구항▼
1. A process for rendering a blood product which comprises a labile blood protein substantially free of lipid-containing viruses without incurring substantial protein denaturation which comprises contacting said blood product with an effective amount of a di- or trialkylphosphate for a period of tim
1. A process for rendering a blood product which comprises a labile blood protein substantially free of lipid-containing viruses without incurring substantial protein denaturation which comprises contacting said blood product with an effective amount of a di- or trialkylphosphate for a period of time sufficient to render said blood product substantially free of lipid-containing viruses without incurring substantial protein denaturation. 2. A process according to claim 1 wherein di- or trialkylphosphate has alkyl groups which contain 1 to 10 carbon atoms. 3. A process according to claim 2 wherein said trialkylphosphate has alkyl groups which contain 2 to 10 carbon atoms. 4. A process according to claim 2 wherein said trialkylphosphate is tri-n-butyl phosphate. 5. A process according to claim 1 wherein said contacting is conducted in the presence of a wetting agent. 6. A process according to claim 5 wherein said wetting agent is a non-ionic detergent. 7. A process according to claim 5 wherein said wetting agent is added to said blood product prior to contacting said blood product with said di- or trialkylphosphate. 8. A process according to claim 5 wherein said wetting agent is added simultaneously with said di- or trialkylphosphate to said blood product. 9. A process according to claim 5 wherein said wetting agent is added after said di- or trialkylphosphate contacts said blood product. 10. A process according to claim 6 wherein said detergent is a partial ester of sorbitol anhydrides. 11. A process according to claim 1 further comprising conducting said contacting in the presence of lipid coated virus inactivating agent selected from the group consisting of ethers and alcohols. 12. A process according to claim 5 further comprising conducting said contacting in the presence of an inactivating agent selected from the group consisting of ethers and alcohols. 13. A process according to claim 1 wherein said blood protein is selected from the group consisting of whole blood, blood plasma, red blood cells, leucocytes, platelet concentrates, a plasma concentrate, a precipitate from any fractionation of such plasma, a supernatant from any fractionation of said plasma, a serum, a cryoprecipitate, a cell lysate and proteins induced in blood cells. 14. A process according to claim 1 wherein said labile blood protein is selected from the group consisting of fibrinogen, cold insoluble globulin, properdin, IgG, IgM, IgA, betaliproprotein, plasmin-inhibitor, factor V, thrombin, antithrombin, isoagglutinins, cerutoplasmin, alpha 1 -lipoprotein, peptidase, transferrin, thyroxine binding globulin, serum esterase, alkaline phosphates, alpha 1 -acid glycoprotein, factor II, factor VII, factor VIII, factor IX, factor X, factor XIII, factor I, immunoglobulins, prealbumin, retinol-binding protein, albumin, alpha-globulins, beta-globulins, gamma-globulins, factor III, the complement components, fibronectin, antithrombin III, hemoglobin, interferon, T-cell growth factor and plasminogen activator. 15. A process according to claim 1 wherein following said contacting with said di- or trialkylphosphate, said di- or trialkylphosphate is removed. 16. A process according to claim 1 wherein said period of time is between about 1 minute and about 30 hours. 17. A process according to claim 1 wherein said contacting is conducted at a temperature of between about 0° C. and about 70° C. 18. A process according to claim 1 wherein said di- or trialkylphosphate is present in an amount between about 0.001% and about 1%. 19. A process according to claim 13 wherein said blood product comprises factor VIII. 20. A process according to claim 13 wherein said blood product comprises factor IX. 21. A process according to claim 1 wherein said blood product is additionally heated for at least 5 hours at 50° to 70° C. 22. A process according to claim 22 wherein the composition which is heated comprises a protein stabilizer which stabilizes a protein against denaturation by heat. 23. A process according to claim 1 wherein said labile blood protein is factor VIII. 24. A process according to claim 1 wherein said labile blood protein is factor VII. 25. A process according to claim 1 wherein said labile blood protein is factor IX. 26. A process according to claim 1 wherein said labile blood protein is factor X. 27. A process according to claim 1 wherein said labile blood protein is fibrinogen. 28. A process according to claim 1 wherein said labile blood protein is fibronectin. 29. A process according to claim 1 wherein said labile blood protein comprises an antibody against infectious hepatitis. 30. A process according to claim 1 wherein said labile blood protein is factor XIII. 31. A process according to claim 1 wherein said labile blood protein is T-cell growth factor. 32. A process according to claim 1 wherein said labile blood protein is a protein of a leucocyte. 33. A process according to claim 1 wherein said labile blood protein is a protein of a red blood cell. 34. A process according to claim 1 wherein said labile blood protein is a protein of a blood platelet concentrate.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (3)
Shanbrom Edward (2252 Liane La. Santa Ana CA 92705), Depyrogenation process.
Lees, Andrew, Activation of polysaccharides via the cyanylating agent, 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), in the preparation of polysaccharide/protein conjugate vaccines.
Lees, Andrew, Activation of polysaccharides via the cyanylating agent, 1-cyanobenzotriazole (1-CBT), in the preparation of polysaccharide/protein conjugate vaccines.
Lees, Andrew, Activation of polysaccharides via the cyanylating agent, 1-cyanoimidazole (1-Cl), in the preparation of polysaccharide/protein conjugate vaccines.
Lees, Andrew, Activation of polysaccharides via the cyanylating agent, 2-cyanopyridazine-3(2H)-one (2-CPO), in the preparation of polysaccharide/protein conjugate vaccines.
Alred, Patricia; Cook, Scott A.; Lebing, Wytold R.; Lee, Douglas C.; Paul, Hanns-Ingolf; Radtke, Klaus-Peter, Chromatographic method for high yield purification and viral inactivation of antibodies.
Alred, Patricia; Cook, Scott A.; Lebing, Wytold R.; Lee, Douglas C.; Paul, Hanns-Ingolf; Radtke, Klaus-Peter, Chromatographic method for high yield purification and viral inactivation of antibodies.
Lebing Wytold ; Alred Patricia ; Lee Douglas C. ; Paul Hanns-Ingolf, Chromatographic method for high yield purification and viral inactivation of antibodies.
Lebing, Wytold R.; Lee, Douglas C.; Radtke, Klaus-Peter; Cook, Scott A.; Paul, Hanns-Ingolf; Alred, Patricia, Chromatographic method for high yield purification and viral inactivation of antibodies.
Annis, Ted C.; Baker, James R.; Hamouda, Tarek, Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof.
Annis, Theodore C.; Baker, James R.; Hamouda, Tarek, Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof.
Horowitz Bernard (New Rochelle NY) Bonomo Richard J. (Hartsdale NY), Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons.
Eran, Harutyun; Hwang, Duk S.; Kosow, David P., Heparin enhanced process for separating antihemophilic factor (Factor VIII) and fibronectin from cryoprecipitate.
Miripol Jeffrey E. (Newark DE) Bilstad Arnold (Deerfield IL) Foley John (Wheeling IL) Glash Dean (McHenry IL) Bratten William R. (Lake Villa IL), Irradiation of blood products.
Yendra Linnau AT; Ernst Hetzl AT; H. Peter Matthiessen AT; Silvia Neppl AT; Wolfgang Schonhofer AT; Hans-Peter Schwarz AT, Method for purification of antithrombin III using an anion exchanger.
Anderle, Heinz; Matthiessen, Peter; Schwarz, Hans-Peter; Turecek, Peter; Kreil, Thomas; Boggs, Daniel R., Method for the validatable inactivation of pathogens in a biological fluid by irradiation.
Dichtelmller Herbert (Sulzbach DEX) Mller Wolfgang (Oberursel DEX) Stephan Wolfgang (Dreieich DEX) Schleussner Hans (Frankfurt am Main DEX), Method of sterilizing plasma or plasma fractions.
Bellotti, Marc; Brewer, Jr., H. Bryan; Akeefe, Hassibullah; Conner, Adam Paul; Perlman, Timothy Jon, Methods and apparatus for creating particle derivatives of HDL with reduced lipid content.
Bellotti, Marc; Brewer, Jr., H. Bryan; Akeefe, Hassibullah; Conner, Adam Paul; Perlman, Timothy Jon, Methods and apparatus for creating particle derivatives of HDL with reduced lipid content.
Bellotti, Marc; Brewer, Jr., H. Bryan; Akeefe, Hassibullah; Conner, Adam Paul; Perlman, Timothy Jon, Methods and apparatus for creating particle derivatives of HDL with reduced lipid content.
Bellotti, Marc; Brewer, Jr., H. Bryan; Akeefe, Hassibullah; Conner, Adam Paul; Perlman, Timothy Jon, Methods and apparatus for creating particle derivatives of HDL with reduced lipid content.
Anderle, Heinz; Matthiessen, Peter; Schwarz, Hans-Peter; Turecek, Peter; Kreil, Thomas; Boggs, Daniel R., Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors.
Anderle, Heinz; Matthiessen, Peter; Schwarz, Hans-Peter; Turecek, Peter; Kreil, Thomas; Boggs, Daniel R., Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors.
Van Holten, Robert W.; Autenrieth, Stephen M., Optimal placement of a robust solvent/detergent process post viral ultrafiltration of an immune gamma globulin.
Boschetti Egisto (Croissy FRX) Girot Pierre (Paris FRX) Guerrier Luc P. (Chilly-Mazarin FRX), Porous support for the removal of small exogenous molecules from biological fluids.
Hwang Duk Sung ; Nario Evelyn ; Lepe Mark ; Luz Lyndon ; Ito Hirokazu ; Takechi Kazuo, Process for increasing the yield of a protein which has been subjected to viral inactivation.
Viswanathan, Chandra; Kuppusamy, Mosuvan; Kamath, Manjunath; Baikar, Vilas; Tanavade, Arati; Prasad, Narahari R.; Dhundi, Ritesh, Process for removal of solvent and detergent from plasma.
Taniguchi T. (Tom) ; Rolf John M. ; Bhattacharya Prabir ; Uemura Yahiro (Roy), Process for separating .alpha.1-proteinase inhibitor from cohn fraction IV1 and IV4 paste.
Hwang Duk S. (South Pasadena CA) Nario Evelyn (Chino Hills CA) Lepe Mark (West Covina CA) Luz Lyndon (Huntington Park CA) Ito Hirokazu (Arcadia CA) Takechi Kazuo (Arcadia CA), Process for seperating alpha-1-proteinase inhibitor from COHN IV1+1V4paste.
Woods Kenneth R. (Sea Cliff NY) Orme Thomas W. (Huntington Station NY), Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synt.
Bomberger,David C.; Chavez,Bryan; Garcia,Pablo E.; Hegwer,Eric; Low,Thomas P.; Malhotra,Ripudaman; Shimon,Jeffrey J., Systems and methods using a solvent for the removal of lipids from fluids.
Bomberger,David C.; Chavez,Bryan; Garcia,Pablo E.; Hegwer,Eric; Low,Thomas P.; Malhotra,Ripudaman; Shimon,Jeffrey J., Systems and methods using multiple solvents for removal of lipids from fluids.
Bomberger,David C.; Chavez,Bryan; Garcia,Pablo E.; Hegwer,Eric; Low,Thomas P.; Malhotra,Ripudaman; Shimon,Jeffrey J., Systems and methods using multiple solvents for the removal of lipids from fluids.
Bomberger,David C.; Chavez,Bryan; Garcia,Pablo E.; Hegwer,Eric; Low,Thomas P.; Malhotra,Ripudaman; Shimon,Jeffrey J., Systems and methods using multiple solvents for the removal of lipids from fluids.
Bomberger,David C.; Chavez,Bryan; Garcia,Pablo E.; Hegwer,Eric; Low,Thomas P.; Malhotra,Ripudaman; Shimon,Jeffrey J., Systems and methods using multiple solvents for the removal of lipids from fluids.
Neurath Alexander R. (New York NY) Horowitz Bernard (New Rochelle NY), Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.